Back to Search
Start Over
Laboratory Testing In Patients Treated With Direct Oral Anticoagulants:A Practical Guide For Clinicians
- Source :
- Douxfils, J, Ageno, W, Samama, C-M, Lessire, S, Ten Cate, H, Verhamme, P, Dogné, J-M & Mullier, F 2018, ' Laboratory Testing In Patients Treated With Direct Oral Anticoagulants : A Practical Guide For Clinicians ', Journal of thrombosis and haemostasis : JTH, vol. 16, no. 2, pp. 209-219 . https://doi.org/10.1111/jth.13912
- Publication Year :
- 2018
-
Abstract
- Click to hear Dr Baglin's perspective on the role of the laboratory in treatment with new oral anticoagulants SUMMARY: One of the key benefits of the direct oral anticoagulants (DOACs) is that they do not require routine laboratory monitoring. Nevertheless, assessment of DOAC exposure and anticoagulant effects may become useful in various clinical scenarios. The five approved DOACs (apixaban, betrixaban, dabigatran etexilate, edoxaban and rivaroxaban) have different characteristics impacting assay selection and the interpretation of results. This article provides an updated overview on (i) which test to use (and their advantages and limitations), (ii) when to assay DOAC levels, (iii) how to interpret the results relating to bleeding risk, emergency situations and perioperative management, and (iv) what is the impact of DOACs on routine and specialized coagulation assays. Assays for anti-Xa or anti-IIa activity are the preferred methods when quantitative information is useful, although the situations in which to test for DOAC levels are still debated. Different reagent sensitivities and variabilities in laboratory calibrations impact assay results. International calibration standards for all specific tests for each DOAC are needed to reduce the inter-laboratory variability and allow inter-study comparisons. The impact of the DOACs on hemostasis testing may cause false-positive or false-negative results; however, these can be minimized by using specific assays and collecting blood samples at trough concentrations. Finally, prospective clinical trials are needed to validate the safety and efficacy of proposed laboratory thresholds in relation to clinical decisions. We offer recommendations on the tests to use for measuring DOACs and practical guidance on laboratory testing to help patient management and avoid diagnostic errors. ispartof: Journal of Thrombosis and Haemostasis vol:16 issue:2 pages:209-219 ispartof: location:England status: published
- Subjects :
- Administration, Oral
COAGULATION ASSAYS
030204 cardiovascular system & hematology
Laboratory testing
chemistry.chemical_compound
Practical management
0302 clinical medicine
HEMOSTASIS TESTS
Rivaroxaban
Edoxaban
Apixaban
dabigatran
rivaroxaban
Blood coagulation test
INVASIVE PROCEDURES
Anticoagulant
Hematology
Dabigatran
030220 oncology & carcinogenesis
Blood Coagulation Tests
Drug Monitoring
medicine.drug
medicine.medical_specialty
DABIGATRAN ETEXILATE
PLASMA-CONCENTRATIONS
medicine.drug_class
EX-VIVO SAMPLES
apixaban
Hemorrhage
Antithrombins
03 medical and health sciences
Predictive Value of Tests
medicine
Humans
Intensive care medicine
Blood Coagulation
business.industry
PERIPROCEDURAL MANAGEMENT
Anticoagulants
Reproducibility of Results
IN-VITRO
PAIN-PROCEDURES
Clinical trial
chemistry
laboratory testing
Betrixaban
ATRIAL-FIBRILLATION
edoxaban
practical management
business
Factor Xa Inhibitors
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Douxfils, J, Ageno, W, Samama, C-M, Lessire, S, Ten Cate, H, Verhamme, P, Dogné, J-M & Mullier, F 2018, ' Laboratory Testing In Patients Treated With Direct Oral Anticoagulants : A Practical Guide For Clinicians ', Journal of thrombosis and haemostasis : JTH, vol. 16, no. 2, pp. 209-219 . https://doi.org/10.1111/jth.13912
- Accession number :
- edsair.doi.dedup.....85dfe11b6bff74485d3a0f9bda18992f
- Full Text :
- https://doi.org/10.1111/jth.13912